Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a report issued on ...

H.C. Wainwright reaffirmed its Buy rating on Northern Dynasty Minerals (NYSE:NAK) with a steady price target of $1.30, representing significant upside from the current trading price of $0.65. The ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

H.C. Wainwright raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $21 from $8 and keeps a Buy rating on the shares. The firm ...

Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

We recently compiled a list of the 10 Trending AI Stocks on Wall Street’s Radar. In this article, we are going to take a look ...

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Northern Dynasty Minerals (NAK – Research Report) ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

H.C. Wainwright has recently reiterated BigBear.ai Holdings Inc (BBAI) stock to Buy rating, as announced on December 30, 2024, according to Finviz. Earlier, on January 9, 2024, Cantor Fitzgerald had ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...